Aileron Therapeutics Inc (OQ:ALRN)

Apr 15, 2024 05:20 pm ET
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and...
Mar 12, 2024 08:00 am ET
Aileron Therapeutics Announces CEO Transition
Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that...
Feb 15, 2024 04:05 pm ET
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, will host a virtual...
Feb 01, 2024 04:30 pm ET
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that...
Oct 31, 2023 12:30 pm ET
Aileron Therapeutics Announces Acquisition of Lung Therapeutics
Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IPF)
Feb 21, 2023 08:30 am ET
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia...
Nov 30, 2022 07:00 am ET
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it received written notice on November 28, 2022 from The...
Nov 10, 2022 08:00 am ET
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it will effect a 1-for-20 reverse stock split of its...
Nov 01, 2022 08:15 am ET
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives today, reported financial results and business highlights for the third quarter...
Oct 26, 2022 06:05 am ET
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR Internat
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today presented detailed results from its completed Phase 1 study of ALRN-6924 in...
Sep 30, 2022 08:41 am ET
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Socie
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced an oral presentation at the European Society for Dermatological...
Sep 22, 2022 08:00 am ET
Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive...
Sep 06, 2022 07:00 am ET
Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that a pre-recorded corporate presentation by Manuel Aivado,...
Aug 15, 2022 04:15 pm ET
Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives today, reported financial results and business highlights for the second quarter...
Aug 01, 2022 07:51 am ET
Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today outlined its strategy to strengthen the company’s Phase 1b...
Jul 08, 2022 08:31 am ET
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, announced today that Manuel Aivado, M.D., Ph.D., President and Chief Executive...
Jun 29, 2022 06:30 am ET
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced interim data from its Phase 1b chemoprotection trial of...
May 19, 2022 07:00 am ET
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced it has treated the first patients in its Phase 1b randomized,...
May 17, 2022 07:00 am ET
Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive...
May 13, 2022 07:00 am ET
Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it will host a virtual KOL investor event on Thursday, May...
May 10, 2022 12:43 pm ET
Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upco
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced a late-breaking oral presentation at the upcoming Society for...
May 05, 2022 04:15 pm ET
Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives today, reported financial results and business highlights for the first quarter...
Apr 21, 2022 08:00 am ET
Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced it has expanded its management team with the appointment of...
Mar 28, 2022 04:20 pm ET
Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today reported business highlights and financial results for the fourth quarter...
Mar 22, 2022 08:04 am ET
Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective to save more patients’ lives, announced today that Manuel Aivado, M.D., Ph.D., President...
Jan 05, 2022 08:04 am ET
Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones
Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective to save more patients’ lives, today provided a business update and outlined the company’s...
Jan 04, 2022 08:45 am ET
Aileron Therapeutics to Present at Upcoming Investor Conferences
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, is pleased to announce that Manuel Aivado, M.D., Ph.D., President and Chief Executive...
Jan 04, 2022 07:00 am ET
CEO Presenting on the Emerging Growth Conference on January 5 Register Now
EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 22nd Emerging Growth Conference. The Emerging...
Dec 20, 2021 10:56 am ET
Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs
Aileron Therapeutics (NASDAQ:ALRN) today issued the following statement regarding the passing of Nobel Laureate Robert H. Grubbs, Ph.D., who served as a member of the company's Scientific Advisory Board since 2011. “We are deeply saddened by the...
Nov 12, 2021 07:50 am ET
Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today reported financial results and business highlights for the third quarter ended...
Oct 07, 2021 09:22 am ET
Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today presented new preclinical data at the AACR-NCI-EORTC International Conference on...
Sep 30, 2021 04:30 pm ET
Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced it will present new preclinical data at the upcoming AACR-NCI-EORTC...
Sep 16, 2021 09:31 am ET
Thinking about buying stock in Aileron Therapeutics, Invacare, Medavail, Rockley Photonics, or Uranium Royalty?
NEW YORK, Sept. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALRN, IVC, MDVL, RKLY, and UROY.
Sep 16, 2021 08:15 am ET
Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today presented new clinical data at the European Society of Medical Oncology (ESMO)...
Sep 10, 2021 08:30 am ET
Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced two upcoming poster presentations at the European Society of Medical...
Sep 07, 2021 04:05 pm ET
Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive...
Aug 27, 2021 07:45 am ET
Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting
Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced a poster presentation showcasing initial findings from its ongoing...
Aug 25, 2021 09:31 am ET
Thinking about buying stock in Jiayin Group, American Resources, Option Care Health, 21Vianet, or Aileron Therapeutics?
NEW YORK, Aug. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JFIN, AREC, OPCH, VNET, and ALRN.
Aug 11, 2021 04:20 pm ET
Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
ALRN-6924 is designed to deliver selective chemoprotection against chemotherapy-induced toxicities via p53 biomarker strategy         Nearly 1 million patients in the U.S. across all cancer types are diagnosed annually with p53-mutated cancer...
Jul 08, 2021 08:15 am ET
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021
Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, announced today that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer,...
Jul 01, 2021 08:00 am ET
Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Aileron Therapeutics, Inc. (Nasdaq: ALRN) today announced that it has initiated  a randomized, double-blind, placebo-controlled clinical trial in the US and in Europe of ALRN-6924 as a chemoprotective agent to treat patients with non-small cell...
Jun 24, 2021 07:00 am ET
Aileron Therapeutics to be Added to the Russell Microcap® Index
Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, announced today that it is set to join the Russell Microcap® Index at the conclusion of...
May 19, 2021 07:00 am ET
Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities
Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, announced today that it will host a key opinion leader (KOL) investor event focused on...
May 11, 2021 04:18 pm ET
Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today reported business highlights and financial results for the first quarter ended...
Mar 24, 2021 04:36 pm ET
Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today reported business highlights and financial results for the fourth quarter and...
Mar 04, 2021 08:30 am ET
Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference
Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the 2021 H.C. Wainwright Global Life Sciences Conference, which is taking place March 9...
Mar 02, 2021 07:00 am ET
Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Aileron Therapeutics, Inc. (Nasdaq: ALRN) today announced that it has expanded the enrollment target for its upcoming Phase 1b clinical trial of ALRN-6924 in patients with non-small cell lung cancer (NSCLC) undergoing chemotherapy. Aileron plans to...
Jan 11, 2021 07:30 am ET
Thinking about buying stock in Nio, Zomedica, Transenterix, Aileron Therapeutics, or BioNano Genomics?
NEW YORK, Jan. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, ZOM, TRXC, ALRN, and BNGO.
Jan 11, 2021 06:30 am ET
Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investm
-- Company plans to initiate the randomized, placebo-controlled Phase 1b NSCLC trial in second quarter 2021, marking expansion of ALRN-6924 clinical development into large cancer indication -- WATERTOWN, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) --...
Jan 06, 2021 09:29 am ET
Aileron Therapeutics Announces $35.9 Million Registered Direct Offering
Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare investors for the purchase and sale of 32,630,983 of its shares of common stock at a purchase price of $1.10 per...
Jan 05, 2021 07:30 am ET
Thinking about buying stock in Aileron Therapeutics, Check Cap, Jaguar Health, Clearside Biomedical, or Gritstone Oncology?
NEW YORK, Jan. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALRN, CHEK, JAGX, CLSD, and GRTS.
Dec 24, 2020 07:31 am ET
Thinking about buying stock in Pfizer, Senseonics Holdings, AIM ImmunoTech, Aileron Therapeutics, or Microvision?
NEW YORK, Dec. 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, SENS, AIM, ALRN, and MVIS.
Dec 21, 2020 08:00 am ET
Aileron Therapeutics Provides Business Update and Outlines 2021 Strategic Priorities
Aileron Therapeutics (NASDAQ:ALRN) today provided a business update and outlined its strategic priorities for 2021, including announcing more details about the design and conduct of a Phase 1b randomized, double-blind, placebo-controlled clinical...
Nov 12, 2020 07:03 pm ET
Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the third quarter ended September 30, 2020. “We recently achieved the critical milestone of clinical proof of concept of ALRN-6924, demonstrating a...
Oct 24, 2020 04:35 am ET
Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium
Aileron Therapeutics (Nasdaq: ALRN) today announced new positive clinical data from its ongoing Phase 1b trial demonstrating clinical proof of concept that treatment with ALRN-6924 prior to second-line topotecan administration resulted in a...
Oct 21, 2020 09:31 am ET
Thinking about buying stock in Staffing 360 Solutions, IBM, Selecta Biosciences, 3M, or Aileron Therapeutics?
NEW YORK, Oct. 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for STAF, IBM, SELB, MMM, and ALRN.
Oct 20, 2020 09:24 am ET
Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium
Aileron Therapeutics (Nasdaq: ALRN) today announced that it will host a conference call and live webcast to discuss results from a Phase 1b proof-of-concept study of ALRN-6924 on Monday, October 26, 2020 at 8:30 a.m. ET. As previously announced by...
Oct 12, 2020 07:00 am ET
Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium
Aileron Therapeutics (Nasdaq: ALRN) today announced that proof-of-concept data from the company’s Phase 1b study of ALRN-6924 will be featured in a late-breaking poster presentation during the 32nd EORTC-NCI-AACR Annual (ENA 2020) Symposium on...
Sep 21, 2020 06:07 pm ET
Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
Aileron Therapeutics, Inc. (NASDAQ: ALRN), today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $15 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor and...
Sep 10, 2020 08:45 am ET
Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference
Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the upcoming H.C. Wainwright Virtual Global Investment Conference, including an update...
Aug 06, 2020 09:31 am ET
Thinking about buying stock in Beam Therapeutics, Digital Turbine, Arbutus Biopharma, Aileron Therapeutics, or Snap Inc?
NEW YORK, Aug. 6, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BEAM, APPS, ABUS, ALRN, and SNAP.
Aug 05, 2020 04:10 pm ET
Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the second quarter ended June 30, 2020. “We continue to make important progress advancing our goal to deliver a novel chemoprotective medicine that can...
Aug 03, 2020 08:10 am ET
Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August
Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences this month. Thursday, August 6, 2020 Event: William Blair Biotech...
Aug 03, 2020 08:00 am ET
Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924
Aileron Therapeutics (NASDAQ:ALRN) announced today that it has completed enrollment in the dose optimization expansion cohort of its ongoing open-label Phase 1b clinical study of ALRN-6924. Aileron is focused on transforming the experience of...
Jun 29, 2020 08:30 am ET
Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotec
Aileron Therapeutics (NASDAQ:ALRN), a biotechnology company advancing a novel chemoprotective therapy for cancer patients, announced today that it has enrolled the first patient in the open-label Phase 1b schedule optimization part of its ongoing...
Jun 10, 2020 09:54 am ET
Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares
Aileron Therapeutics (NASDAQ: ALRN) announced today the closing of its underwritten public offering of its common stock, including the exercise by the underwriter of their option to purchase an additional 1,071,149 shares at the public offering...
Jun 04, 2020 09:15 am ET
Aileron Therapeutics Announces Pricing of Public Offering of Common Stock
Aileron Therapeutics (NASDAQ: ALRN) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $1.10 per share, for aggregate gross proceeds of $10.0 million, before...
Jun 03, 2020 04:01 pm ET
Aileron Therapeutics Announces Proposed Public Offering of Common Stock
Aileron Therapeutics (NASDAQ: ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. Aileron also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares...
Jun 01, 2020 09:31 am ET
Thinking about buying stock in Ovid Therapeutics, Celsion Corp, Aileron Therapeutics, Cronos Group, or Bank of America?
NEW YORK, June 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OVID, CLSN, ALRN, CRON, and BAC.
Jun 01, 2020 07:00 am ET
Aileron Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities During Treatment for Small Cell Lung Cancer
Aileron Therapeutics (NASDAQ:ALRN) announced today positive interim data from the open-label Phase 1b dose optimization part of its ongoing Phase 1b/2 clinical trial. In this trial, ALRN-6924 is being evaluated as an agent to protect patients...
May 28, 2020 09:31 am ET
Thinking about buying stock in PhaseBio Pharmaceuticals, Aileron Therapeutics, JetBlue Airways, Aurora Cannabis, or Remark Holdings?
NEW YORK, May 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHAS, ALRN, JBLU, ACB, and MARK.
May 27, 2020 08:30 am ET
Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent
Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients with small cell lung cancer (SCLC)...
May 11, 2020 08:30 am ET
Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the first quarter ended March 31, 2020. “We continue to advance ALRN-6924 as a chemoprotection agent for cancer patients, even as the world...
Apr 22, 2020 08:30 am ET
Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020
Aileron Therapeutics (NASDAQ:ALRN) today announced plans to report interim results from their Phase 1b/2 clinical trial of ALRN-6924 in small cell lung cancer (SCLC). In this trial, ALRN-6924 is being evaluated as an agent to protect cancer...
Mar 30, 2020 04:16 pm ET
Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019. “We continue...
Dec 18, 2019 08:30 am ET
Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer, effective immediately. Mr. Wanstall...
Nov 07, 2019 07:30 am ET
Aileron Therapeutics Reports Third Quarter 2019 Results
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today reported business highlights and financial results for the third quarter ended September 30, 2019. “We have generated...
Oct 31, 2019 08:30 am ET
Aileron Therapeutics to Report Third Quarter 2019 Financial Results on November 7th
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the Company will host a conference call and webcast at 8:30 a.m. ET on Thursday, November 7, 2019 to report...
Oct 29, 2019 08:00 am ET
Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference
Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, presented new data at the 2019 AACR-NCI-EORTC Conference from nonclinical studies in which ALRN-6924, a dual inhibitor of MDM2 and...
Oct 21, 2019 08:00 am ET
Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th
Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, is scheduled to present new nonclinical data demonstrating that in in vivo studies ALRN-6924, a dual inhibitor of MDM2 and MDMX,...
Oct 16, 2019 08:30 am ET
Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent
Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the first patient has completed the initial cycle of treatment in the Company’s first clinical trial evaluating...
Sep 28, 2019 07:30 am ET
Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, announced the presentation of interim results from its ongoing Phase 2a clinical trial evaluating the...
Sep 24, 2019 05:00 pm ET
Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society
Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, today announced that an abstract on interim Phase 2a data for the Company’s lead product candidate,...
Sep 09, 2019 08:00 am ET
Aileron Therapeutics Announces Management Change
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Don Dougherty, its current Chief Financial Officer, will be leaving Aileron...
Sep 03, 2019 05:10 pm ET
Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Manuel Aivado, MD, PhD, President & Chief Executive Officer, will  present a...
Aug 06, 2019 04:10 pm ET
Aileron Therapeutics Reports Second Quarter 2019 Financial Results
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of cell permeating peptide therapeutics for cancers and other diseases, today reported business highlights and financial results for the quarter ended June 30, 2019....
Jul 30, 2019 07:03 pm ET
Aileron Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Manuel Aivado, MD, PhD, President & Chief Executive Officer, will provide a...
Jul 30, 2019 04:47 pm ET
Aileron Therapeutics to Report Second Quarter 2019 Financial Results on August 6, 2019
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that the Company will report financial results for its second quarter ended June...
Jun 27, 2019 08:00 am ET
Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational...
Jun 24, 2019 08:00 am ET
Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that William (“Bill”) T. McKee and Josef (“Joe”) H. von Rickenbach have been...
May 30, 2019 08:00 am ET
Aileron Therapeutics to Present at the Jefferies 2019 Healthcare Conference
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Manuel Aivado, MD, PhD, President & Chief Executive Officer, will present a...
May 08, 2019 04:57 pm ET
Aileron Therapeutics Reports First Quarter 2019 Financial Results
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today reported business highlights and financial results for the first quarter ended March 31,...
May 01, 2019 06:31 pm ET
Aileron Therapeutics to Report First Quarter 2019 Financial Results on May 8
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that the Company will report financial results for its first quarter ended March...
Apr 03, 2019 12:15 pm ET
Aileron Therapeutics Completes $26M Private Placement
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, announced today the closing of its previously announced private placement of Aileron common...
Mar 29, 2019 09:00 am ET
Aileron Therapeutics Announces Pricing of $26M Private Placement
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, announced today that it has entered into a securities purchase agreement with a group of...
Mar 04, 2019 09:00 am ET
Aileron Therapeutics Appoints Kathryn Gregory as Chief Business Officer
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Kathryn Gregory has been named Chief Business Officer (CBO). In this role,...
Jan 16, 2019 12:47 pm ET
Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers
Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that the first patient has been enrolled in a Phase 2a expansion cohort intended...
Dec 04, 2018 09:13 am ET
Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, announced today the presentation of two posters at the 60th Annual American Society of...
Nov 27, 2018 08:00 am ET
Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that it has entered into a clinical trial collaboration with Pfizer to evaluate...
Nov 19, 2018 08:25 am ET
Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Arcimoto, Inc. (NASDAQ:FUV), ADOMANI, Inc. (NASDAQ:ADOM), Lipocine Inc....
Nov 07, 2018 04:10 pm ET
Aileron Therapeutics Reports Third Quarter 2018 Financial Results
Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today reported business highlights and financial results for the third quarter ended September...
Nov 05, 2018 04:05 pm ET
Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer
Aileron Therapeutics (NASDAQ:ALRN), the clinical stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that Vojislav (Vojo) Vukovic, MD, PhD, has been named Chief Medical Officer...
Nov 01, 2018 04:05 pm ET
Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced an agreement with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center...
Oct 30, 2018 04:05 pm ET
Aileron Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018
Aileron Therapeutics (NASDAQ: ALRN), the clinical stage leader in the field of stabilized, cell-permeable peptides to treat cancer and other diseases, today announced that the Company will report financial results for its third quarter ended...
Oct 19, 2018 08:00 am ET
Aileron Announces Poster Presentations at Two Scientific Conferences in November
Aileron Therapeutics (Nasdaq: ALRN), the clinical stage leader in the discovery and development of engineered cell-penetrating peptides, today announced that two abstracts for the company’s lead drug, ALRN-6924, will be presented, one each at the...
Sep 06, 2018 09:00 am ET
Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that Manuel Aivado, MD, PhD, has been named President and Chief Executive Officer and...
Aug 07, 2018 04:15 pm ET
Aileron Therapeutics Reports Second Quarter 2018 Financial Results
Aileron Therapeutics (Nasdaq:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today reported business highlights and financial results for the second quarter ended June 30, 2018....
Aug 02, 2018 07:00 am ET
Aileron Therapeutics to Present at the Canaccord Genuity 38th Annual Growth Conference
Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that Manuel Aivado, SVP and Chief Medical Officer, will present at the Canaccord Genuity 38th Annual Growth...
Jul 31, 2018 07:00 am ET
Aileron Therapeutics to Report Second Quarter 2018 Financial Results on August 7, 2018
Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that the Company will report its second quarter 2018 financial results on Tuesday, August 7, 2018 after the...
May 29, 2018 07:00 am ET
Aileron Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that Manuel Aivado, CMO and CSO, will present at the Jefferies 2018 Global Healthcare Conference being held...
May 22, 2018 05:00 am ET
Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer Institute
Aileron Therapeutics (Nasdaq:ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced the publication of nonclinical results in Nature Communications demonstrating the anti-cancer potential of...
May 15, 2018 04:05 pm ET
Aileron Therapeutics Announces Changes to Management
Aileron Therapeutics (Nasdaq:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that Joseph A. Yanchik III has resigned as President and Chief Executive Officer of the...
May 09, 2018 04:03 pm ET
Aileron Therapeutics Reports First Quarter 2018 Financial Results
Aileron Therapeutics (Nasdaq:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today reported business highlights and financial results for the first quarter ended March 31, 2018. “In the...
Apr 11, 2018 04:05 pm ET
Aileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid Leukemia
Nonclinical data featured in Science Translational Medicine show dual inhibition of MDM2 and MDMX restored p53 function and demonstrated strong response rates in AML model
Apr 02, 2018 04:09 pm ET
Aileron Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Encouraging interim clinical results from studies of ALRN-6924 and progress against new programs support advancement and expansion of portfolio development plan
Mar 28, 2018 07:00 am ET
Aileron Therapeutics Announces Expansion of Scientific Advisory Board
Drs. Druker, List and Prives join Aileron’s pioneering efforts to advance its stapled peptide approach to restoring p53’s cancer-fighting function  
Mar 19, 2018 07:00 am ET
Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors
CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptides developing therapeutics for cancers and other diseases, today announced the appointment of Jeffrey A. Bailey as Chairman of...
Dec 11, 2017 04:30 pm ET
Nov 09, 2017 04:18 pm ET
Aileron Therapeutics Reports Third Quarter 2017 Financial Results
Company continues to advance clinical trials of lead product candidate ALRN-6924 in PTCL and AML/MDS
Nov 01, 2017 09:19 am ET
Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting
Two abstracts selected for oral presentations, highlighting the potential of p53-reactivating ALRN-6924 in the treatment of PTCL and AML
Aug 10, 2017 04:10 pm ET
Aileron Therapeutics Reports Second Quarter 2017 Financial Results
Initial clinical data showing anti-tumor activity with ALRN-6924 presented at ASCO 2017 -Presentation selected for Best of ASCO Meetings...
Jun 28, 2017 10:06 pm ET
Aileron Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, today announced the pricing of its initial public offering of 3,750,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. All of the shares are being offered by Aileron. In addition, Aileron has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of common stock from the co...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.